vs
Side-by-side financial comparison of Gain Therapeutics, Inc. (GANX) and ODYSSEY MARINE EXPLORATION INC (OMEX). Click either name above to swap in a different company.
Gain Therapeutics, Inc. is the larger business by last-quarter revenue ($105.4K vs $61.0K, roughly 1.7× ODYSSEY MARINE EXPLORATION INC). Gain Therapeutics, Inc. runs the higher net margin — -4255.7% vs -21439.5%, a 17183.8% gap on every dollar of revenue. ODYSSEY MARINE EXPLORATION INC produced more free cash flow last quarter ($-2.1M vs $-6.1M).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Odyssey Marine Exploration, Inc. is an American company engaged in deep-ocean exploration with a focus on the exploration, development and extraction of subsea mineral resources. Starting out as a shipwreck pioneer, Odyssey has discovered some of the most famous deep-ocean shipwrecks in history, including Ancona, Gairsoppa, Nuestra Señora de las Mercedes, Republic, and HMS Victory. Their work has been featured on the Discovery Channel, PBS and National Geographic.
GANX vs OMEX — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.4K | $61.0K |
| Net Profit | $-4.5M | $-13.1M |
| Gross Margin | — | — |
| Operating Margin | -4230.3% | -3494.4% |
| Net Margin | -4255.7% | -21439.5% |
| Revenue YoY | — | -71.5% |
| Net Profit YoY | 4.9% | -170.0% |
| EPS (diluted) | $-0.17 | $-0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $61.0K | ||
| Q2 25 | — | $135.0K | ||
| Q1 25 | — | $135.0K | ||
| Q4 24 | — | $136.1K | ||
| Q3 24 | $105.4K | $213.9K | ||
| Q2 24 | $84.5K | $215.6K | ||
| Q1 24 | $115.3K | $203.1K |
| Q3 25 | — | $-13.1M | ||
| Q2 25 | — | $-14.8M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $-5.0M | ||
| Q3 24 | $-4.5M | $18.7M | ||
| Q2 24 | $-8.1M | $-1.5M | ||
| Q1 24 | $-4.0M | $3.5M |
| Q3 25 | — | -3494.4% | ||
| Q2 25 | — | -3241.0% | ||
| Q1 25 | — | -1648.6% | ||
| Q4 24 | — | -1031.0% | ||
| Q3 24 | -4230.3% | -1340.9% | ||
| Q2 24 | -9680.3% | -1399.1% | ||
| Q1 24 | -3796.7% | -2323.0% |
| Q3 25 | — | -21439.5% | ||
| Q2 25 | — | -10998.5% | ||
| Q1 25 | — | 1660.4% | ||
| Q4 24 | — | -3673.4% | ||
| Q3 24 | -4255.7% | 8736.9% | ||
| Q2 24 | -9633.2% | -708.4% | ||
| Q1 24 | -3481.4% | 1722.6% |
| Q3 25 | — | $-0.31 | ||
| Q2 25 | — | $-0.48 | ||
| Q1 25 | — | $0.01 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | $-0.17 | $0.13 | ||
| Q2 24 | $-0.42 | $-0.07 | ||
| Q1 24 | $-0.22 | $-0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.0M | $5.8M |
| Total DebtLower is stronger | $494.4K | — |
| Stockholders' EquityBook value | $8.9M | $-45.4M |
| Total Assets | $14.4M | $17.7M |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | $12.0M | $2.9M | ||
| Q2 24 | $16.9M | $7.6M | ||
| Q1 24 | $12.7M | $2.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $494.4K | — | ||
| Q2 24 | $486.4K | — | ||
| Q1 24 | $507.7K | — |
| Q3 25 | — | $-45.4M | ||
| Q2 25 | — | $-52.8M | ||
| Q1 25 | — | $-13.9M | ||
| Q4 24 | — | $-16.2M | ||
| Q3 24 | $8.9M | $-16.1M | ||
| Q2 24 | $11.8M | $-35.7M | ||
| Q1 24 | $8.6M | $-35.1M |
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $16.6M | ||
| Q1 25 | — | $15.8M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $14.4M | $21.8M | ||
| Q2 24 | $19.2M | $26.3M | ||
| Q1 24 | $14.6M | $20.6M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.1M | $-2.1M |
| Free Cash FlowOCF − Capex | $-6.1M | $-2.1M |
| FCF MarginFCF / Revenue | -5764.6% | -3438.2% |
| Capex IntensityCapex / Revenue | 0.0% | 2.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | $-6.1M | $-1.6M | ||
| Q2 24 | $-5.8M | $5.6M | ||
| Q1 24 | $-3.6M | $-1.7M |
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | $-6.1M | $-1.6M | ||
| Q2 24 | — | $5.6M | ||
| Q1 24 | — | $-1.8M |
| Q3 25 | — | -3438.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1302.1% | ||
| Q3 24 | -5764.6% | -728.7% | ||
| Q2 24 | — | 2605.0% | ||
| Q1 24 | — | -873.2% |
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | 0.0% | 1.9% | ||
| Q2 24 | — | 9.1% | ||
| Q1 24 | — | 51.2% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.87× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.08× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
